Multicenter	 O
,	 O
randomised	 O
,	 O
open	 O
-	 O
label	 O
,	 O
non	 O
-	 O
comparative	 O
phase	 O
2	 O
trial	 O
on	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
the	 O
combination	 O
of	 O
[P1]	 O
bevacizumab	 O
and	 O
trabectedin	 O
[P2]	 O
with	 O
or	 O
without	 O
carboplatin	 O
in	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
recurrent	 O
ovarian	 O
cancer	 O
Multicenter	 O
,	 O
randomised	 O
,	 O
open	 O
-	 O
label	 O
,	 O
non	 O
-	 O
comparative	 O
phase	 O
2	 O
trial	 O
on	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
the	 O
combination	 O
of	 O
bevacizumab	 O
and	 O
trabectedin	 O
with	 O
or	 O
without	 O
carboplatin	 O
in	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
recurrent	 O
ovarian	 O
cancer	 O
20	 O
September	 O
2019	 O
20	 O
September	 O
2019	 O
NicolettaColombo	 O

Multicenter	 O
,	 O
randomised	 O
,	 O
open	 O
-	 O
label	 O
,	 O
non	 O
-	 O
comparative	 O
phase	 O
2	 O
trial	 O
on	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
the	 O
combination	 O
of	 O
bevacizumab	 O
and	 O
trabectedin	 O
with	 O
or	 O
without	 O
[P1]	 O
carboplatin	 O
[P2]	 O
in	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
recurrent	 O
ovarian	 O
cancer	 O
Multicenter	 O
,	 O
randomised	 O
,	 O
open	 O
-	 O
label	 O
,	 O
non	 O
-	 O
comparative	 O
phase	 O
2	 O
trial	 O
on	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
the	 O
combination	 O
of	 O
bevacizumab	 O
and	 O
trabectedin	 O
with	 O
or	 O
without	 O
carboplatin	 O
in	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
recurrent	 O
ovarian	 O
cancer	 O
20	 O
September	 O
2019	 O
20	 O
September	 O
2019	 O
NicolettaColombo	 O

Multicenter	 O
,	 O
randomised	 O
,	 O
open	 O
-	 O
label	 O
,	 O
non	 O
-	 O
comparative	 O
phase	 O
2	 O
trial	 O
on	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
the	 O
combination	 O
of	 O
bevacizumab	 O
and	 O
trabectedin	 O
with	 O
or	 O
without	 O
carboplatin	 O
in	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
recurrent	 O
ovarian	 O
cancer	 O
Multicenter	 O
,	 O
randomised	 O
,	 O
open	 O
-	 O
label	 O
,	 O
non	 O
-	 O
comparative	 O
phase	 O
2	 O
trial	 O
on	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
the	 O
combination	 O
of	 O
bevacizumab	 O
and	 O
[P1]	 O
trabectedin	 O
[P2]	 O
with	 O
or	 O
without	 O
carboplatin	 O
in	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
recurrent	 O
ovarian	 O
cancer	 O
20	 O
September	 O
2019	 O
20	 O
September	 O
2019	 O
NicolettaColombo	 O

Multicenter	 O
,	 O
randomised	 O
,	 O
open	 O
-	 O
label	 O
,	 O
non	 O
-	 O
comparative	 O
phase	 O
2	 O
trial	 O
on	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
the	 O
combination	 O
of	 O
bevacizumab	 O
and	 O
trabectedin	 O
with	 O
or	 O
without	 O
carboplatin	 O
in	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
recurrent	 O
ovarian	 O
cancer	 O
Multicenter	 O
,	 O
randomised	 O
,	 O
open	 O
-	 O
label	 O
,	 O
non	 O
-	 O
comparative	 O
phase	 O
2	 O
trial	 O
on	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
the	 O
combination	 O
of	 O
bevacizumab	 O
and	 O
trabectedin	 O
with	 O
or	 O
without	 O
[P1]	 O
carboplatin	 O
[P2]	 O
in	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
recurrent	 O
ovarian	 O
cancer	 O
20	 O
September	 O
2019	 O
20	 O
September	 O
2019	 O
NicolettaColombo	 O

Multicenter	 O
,	 O
randomised	 O
,	 O
open	 O
-	 O
label	 O
,	 O
non	 O
-	 O
comparative	 O
phase	 O
2	 O
trial	 O
on	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
the	 O
combination	 O
of	 O
[P1]	 O
bevacizumab	 O
and	 O
trabectedin	 O
[P2]	 O
with	 O
or	 O
without	 O
carboplatin	 B-METRIC
in	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
recurrent	 O
ovarian	 O
cancer	 O
20	 O
September	 O
2019	 O

Multicenter	 O
,	 O
randomised	 O
,	 O
open	 O
-	 O
label	 O
,	 O
non	 O
-	 O
comparative	 O
phase	 O
2	 O
trial	 O
on	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
the	 O
combination	 O
of	 O
[P1]	 O
bevacizumab	 O
[P2]	 O
and	 O
trabectedin	 O
with	 O
or	 O
without	 O
carboplatin	 O
in	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
recurrent	 O
ovarian	 O
cancer	 O
NicolettaColombo	 O

Multicenter	 O
,	 O
randomised	 O
,	 O
open	 O
-	 O
label	 O
,	 O
non	 O
-	 O
comparative	 O
phase	 O
2	 O
trial	 O
on	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
the	 O
combination	 O
of	 O
bevacizumab	 O
and	 O
[P1]	 O
trabectedin	 O
[P2]	 O
with	 O
or	 O
without	 O
carboplatin	 O
in	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
recurrent	 O
ovarian	 O
cancer	 O
NicolettaColombo	 O

Multicenter	 O
,	 O
randomised	 O
,	 O
open	 O
-	 O
label	 O
,	 O
non	 O
-	 O
comparative	 O
phase	 O
2	 O
trial	 O
on	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
the	 O
combination	 O
of	 O
bevacizumab	 O
and	 O
trabectedin	 O
with	 O
or	 O
without	 O
[P1]	 O
carboplatin	 O
[P2]	 O
in	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
recurrent	 O
ovarian	 O
cancer	 O
NicolettaColombo	 O

Italy	 O
Ginecologica	 O
,	 O
Milano	 O
Italy	 O
Multicenter	 O
,	 O
randomised	 O
,	 O
open	 O
-	 O
label	 O
,	 O
non	 O
-	 O
comparative	 O
phase	 O
2	 O
trial	 O
on	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
the	 O
combination	 O
of	 O
[P1]	 O
bevacizumab	 O
[P2]	 O
and	 O
trabectedin	 O
with	 O
or	 O
without	 O
carboplatin	 O
in	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
recurrent	 O
ovarian	 O
cancer	 O
20	 O
September	 O
2019	 O
20	 O
September	 O
2019	 O
20	 O
September	 O
2019	 O
10.1038	 O
/	 O
s41416	 O
-	 O
019	 O
-	 O
0584	 O
-	 O
5	 O
Received	 O
:	 O
28	 O
February	 O
2019	 O
Revised	 O
:	 O
27	 O
August	 O
2019	 O
Accepted	 O
:	 O
30	 O
August	 O
2019	 O

Italy	 O
Ginecologica	 O
,	 O
Milano	 O
Italy	 O
Multicenter	 O
,	 O
randomised	 O
,	 O
open	 O
-	 O
label	 O
,	 O
non	 O
-	 O
comparative	 O
phase	 O
2	 O
trial	 O
on	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
the	 O
combination	 O
of	 O
bevacizumab	 O
and	 O
[P1]	 O
trabectedin	 O
[P2]	 O
with	 O
or	 O
without	 O
carboplatin	 O
in	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
recurrent	 O
ovarian	 O
cancer	 O
20	 O
September	 O
2019	 O
20	 O
September	 O
2019	 O
20	 O
September	 O
2019	 O
10.1038	 O
/	 O
s41416	 O
-	 O
019	 O
-	 O
0584	 O
-	 O
5	 O
Received	 O
:	 O
28	 O
February	 O
2019	 O
Revised	 O
:	 O
27	 O
August	 O
2019	 O
Accepted	 O
:	 O
30	 O
August	 O
2019	 O

Italy	 O
Ginecologica	 O
,	 O
Milano	 O
Italy	 O
Multicenter	 O
,	 O
randomised	 O
,	 O
open	 O
-	 O
label	 O
,	 O
non	 O
-	 O
comparative	 O
phase	 O
2	 O
trial	 O
on	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
the	 O
combination	 O
of	 O
bevacizumab	 O
and	 O
trabectedin	 O
with	 O
or	 O
without	 O
[P1]	 O
carboplatin	 O
[P2]	 O
in	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
recurrent	 O
ovarian	 O
cancer	 O
20	 O
September	 O
2019	 O
20	 O
September	 O
2019	 O
20	 O
September	 O
2019	 O
10.1038	 O
/	 O
s41416	 O
-	 O
019	 O
-	 O
0584	 O
-	 O
5	 O
Received	 O
:	 O
28	 O
February	 O
2019	 O
Revised	 O
:	 O
27	 O
August	 O
2019	 O
Accepted	 O
:	 O
30	 O
August	 O
2019	 O

Patients	 O
entering	 O
the	 O
[P1]	 O
BT	 O
arm	 O
[P2]	 O
received	 O
trabectedin	 O
.	 O

Patients	 O
entering	 O
the	 O
BT	 O
arm	 O
received	 O
[P1]	 O
trabectedin	 O
[P2]	 O
.	 O

Patients	 O
received	 O
[P1]	 O
bevacizumab	 O
[P2]	 O
15	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
kg	 I-DOSAGE
iv	 I-DOSAGE
on	 I-DOSAGE
day	 I-DOSAGE
1	 I-DOSAGE
every	 I-DOSAGE
21	 I-DOSAGE
days	 I-DOSAGE
.	 O

From	 O
cycles	 B-DOSAGE
1	 I-DOSAGE
-	 I-DOSAGE
6	 I-DOSAGE
,	 O
patients	 O
in	 O
the	 O
[P1]	 O
BT+C	 O
arm	 O
[P2]	 O
,	 O
received	 O
carboplatin	 O
AUC	 B-DOSAGE
4	 I-DOSAGE
on	 I-DOSAGE
day	 I-DOSAGE
1	 I-DOSAGE
every	 I-DOSAGE
28	 I-DOSAGE
days	 I-DOSAGE
,	 O
trabectedin	 O
0.8	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
on	 I-DOSAGE
day	 I-DOSAGE
1	 I-DOSAGE
every	 I-DOSAGE
28	 I-DOSAGE
days	 I-DOSAGE
,	 O
bevacizumab	 O
10	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
kg	 I-DOSAGE
on	 I-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
and	 I-DOSAGE
15	 I-DOSAGE
.	 O

From	 O
cycles	 B-DOSAGE
1	 I-DOSAGE
-	 I-DOSAGE
6	 I-DOSAGE
,	 O
patients	 O
in	 O
the	 O
BT+C	 O
arm	 O
,	 O
received	 O
[P1]	 O
carboplatin	 O
[P2]	 O
AUC	 B-DOSAGE
4	 I-DOSAGE
on	 I-DOSAGE
day	 I-DOSAGE
1	 I-DOSAGE
every	 I-DOSAGE
28	 I-DOSAGE
days	 I-DOSAGE
,	 O
trabectedin	 O
0.8	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
on	 I-DOSAGE
day	 I-DOSAGE
1	 I-DOSAGE
every	 I-DOSAGE
28	 I-DOSAGE
days	 I-DOSAGE
,	 O
bevacizumab	 O
10	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
kg	 I-DOSAGE
on	 I-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
and	 I-DOSAGE
15	 I-DOSAGE
.	 O

From	 O
cycles	 B-DOSAGE
1	 I-DOSAGE
-	 I-DOSAGE
6	 I-DOSAGE
,	 O
patients	 O
in	 O
the	 O
BT+C	 O
arm	 O
,	 O
received	 O
carboplatin	 O
AUC	 B-DOSAGE
4	 I-DOSAGE
on	 I-DOSAGE
day	 I-DOSAGE
1	 I-DOSAGE
every	 I-DOSAGE
28	 I-DOSAGE
days	 I-DOSAGE
,	 O
[P1]	 O
trabectedin	 O
[P2]	 O
0.8	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
on	 I-DOSAGE
day	 I-DOSAGE
1	 I-DOSAGE
every	 I-DOSAGE
28	 I-DOSAGE
days	 I-DOSAGE
,	 O
bevacizumab	 O
10	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
kg	 I-DOSAGE
on	 I-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
and	 I-DOSAGE
15	 I-DOSAGE
.	 O

From	 O
cycles	 B-DOSAGE
1	 I-DOSAGE
-	 I-DOSAGE
6	 I-DOSAGE
,	 O
patients	 O
in	 O
the	 O
BT+C	 O
arm	 O
,	 O
received	 O
carboplatin	 O
AUC	 B-DOSAGE
4	 I-DOSAGE
on	 I-DOSAGE
day	 I-DOSAGE
1	 I-DOSAGE
every	 I-DOSAGE
28	 I-DOSAGE
days	 I-DOSAGE
,	 O
trabectedin	 O
0.8	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
on	 I-DOSAGE
day	 I-DOSAGE
1	 I-DOSAGE
every	 I-DOSAGE
28	 I-DOSAGE
days	 I-DOSAGE
,	 O
[P1]	 O
bevacizumab	 O
[P2]	 O
10	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
kg	 I-DOSAGE
on	 I-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
and	 I-DOSAGE
15	 I-DOSAGE
.	 O

For	 O
the	 O
[P1]	 O
BT	 O
arm	 O
[P2]	 O
we	 O
assumed	 O
that	 O
35	 O
%	 O
PFS-6	 B-METRIC
(	 O
p	 O
0	 O
)	 O
or	 O
less	 O
would	 O
mean	 O
the	 O
combination	 O
was	 O
of	 O
no	 O
therapeutic	 O
interest	 O
.	 O

For	 O
the	 O
[P1]	 O
BT	 O
[P2]	 O
drug	 O
combination	 O
to	 O
deserve	 O
further	 O
development	 O
we	 O
set	 O
a	 O
target	 O
PFS-6	 B-METRIC
of	 O
60	 O
%	 O
(	 O
p	 O
1	 O
)	 O
.	 O

For	 O
the	 O
[P1]	 O
BT+C	 O
arm	 O
[P2]	 O
we	 O
took	 O
PFS-6	 B-METRIC
40	 O
%	 O
at	 O
p	 O
0	 O
=	 O
and	 O
65	 O
%	 O
at	 O
p	 O
1	 O
=	 O
.	 O

[P1]	 O
BT	 O
arm	 O
[P2]	 O
From	 O
July	 O
2013	 O
through	 O
December	 O
2016	 O
,	 O
50	 O
patients	 O
were	 O
randomised	 O
/	 O
enroled	 O
in	 O
the	 O
BT	 O
arm	 O
.	 O

BT	 O
arm	 O
From	 O
July	 O
2013	 O
through	 O
December	 O
2016	 O
,	 O
50	 O
patients	 O
were	 O
randomised	 O
/	 O
enroled	 O
in	 O
the	 O
[P1]	 O
BT	 O
arm	 O
[P2]	 O
.	 O

At	 O
analysis	 O
,	 O
three	 O
patients	 O
were	 O
still	 O
on	 O
treatment	 O
with	 O
[P1]	 O
BT	 O
[P2]	 O
.	 O

Of	 O
the	 O
44	 O
patients	 O
who	 O
had	 O
discontinued	 O
treatment	 O
at	 O
the	 O
time	 O
of	 O
analysis	 O
,	 O
[P1]	 O
bevacizumab	 O
[P2]	 O
and/	 O
or	 O
trabectedin	 O
had	 O
been	 O
discontinued	 O
for	 O
causes	 O
independent	 O
of	 O
disease	 O
progression	 O
in	 O
17	 O
(	 O
39	 O
%	 O
)	 O
and	 O
of	 O
these	 O
,	 O
12(27	 O
%	 O
)	 O
for	 O
toxicity	 O
or	 O
SAE	 O
.	 O

Of	 O
the	 O
44	 O
patients	 O
who	 O
had	 O
discontinued	 O
treatment	 O
at	 O
the	 O
time	 O
of	 O
analysis	 O
,	 O
bevacizumab	 O
and/	 O
or	 O
[P1]	 O
trabectedin	 O
[P2]	 O
had	 O
been	 O
discontinued	 O
for	 O
causes	 O
independent	 O
of	 O
disease	 O
progression	 O
in	 O
17	 O
(	 O
39	 O
%	 O
)	 O
and	 O
of	 O
these	 O
,	 O
12(27	 O
%	 O
)	 O
for	 O
toxicity	 O
or	 O
SAE	 O
.	 O

The	 O
median	 O
number	 O
of	 O
[P1]	 O
BT	 O
[P2]	 O
cycles	 O
was	 O
10	 O
(	 O
IQR	 O
:	 O
6	 O
-	 O
16	 O
;	 O
range	 O
2	 O
-	 O
34	 O
)	 O
;	 O
27/47	 O
(	 O
57	 O
%	 O
)	 O
patients	 O
received	 O
ten	 O
or	 O
more	 O
cycles	 O
of	 O
BT	 O
.	 O

The	 O
median	 O
number	 O
of	 O
BT	 O
cycles	 O
was	 O
10	 O
(	 O
IQR	 O
:	 O
6	 O
-	 O
16	 O
;	 O
range	 O
2	 O
-	 O
34	 O
)	 O
;	 O
27/47	 O
(	 O
57	 O
%	 O
)	 O
patients	 O
received	 O
ten	 O
or	 O
more	 O
cycles	 O
of	 O
[P1]	 O
BT	 O
[P2]	 O
.	 O

The	 O
[P1]	 O
BT	 O
[P2]	 O
safety	 O
population	 O
included	 O
47	 O
patients	 O
.	 O

One	 O
of	 O
these	 O
was	 O
fatal	 O
as	 O
the	 O
patient	 O
died	 O
of	 O
bowel	 O
perforation	 O
30	 O
days	 O
after	 O
the	 O
sixth	 O
course	 O
of	 O
[P1]	 O
BT	 O
[P2]	 O
.	 O

The	 O
clinician	 O
reported	 O
a	 O
causal	 O
relation	 O
with	 O
[P1]	 O
bevacizumab	 O
[P2]	 O
.	 O

From	 O
July	 O
2013	 O
through	 O
March	 O
2016	 O
,	 O
21	 O
patients	 O
were	 O
randomised	 O
to	 O
the	 O
[P1]	 O
BT+C	 O
arm	 O
[P2]	 O
.	 O

Adherence	 O
to	 O
treatment	 O
was	 O
problematic	 O
for	 O
8/20	 O
patients	 O
(	 O
40	 O
%	 O
)	 O
who	 O
stopped	 O
[P1]	 O
carboplatin	 O
[P2]	 O
before	 O
six	 O
cycles	 O
while	 O
continuing	 O
with	 O
BT	 O
.	 O

Adherence	 O
to	 O
treatment	 O
was	 O
problematic	 O
for	 O
8/20	 O
patients	 O
(	 O
40	 O
%	 O
)	 O
who	 O
stopped	 O
carboplatin	 O
before	 O
six	 O
cycles	 O
while	 O
continuing	 O
with	 O
[P1]	 O
BT	 O
[P2]	 O
.	 O

Five	 O
of	 O
these	 O
eight	 O
had	 O
an	 O
allergic	 O
reaction	 O
to	 O
carboplatin	 O
and	 O
three	 O
stopped	 O
[P1]	 O
carboplatin	 O
[P2]	 O
because	 O
of	 O
haematologic	 O
toxicity	 O
.	 O

The	 O
median	 O
number	 O
of	 O
[P1]	 O
carboplatin	 O
[P2]	 O
cycles	 O
was	 O
6	 O
(	 O
IQR	 O
:	 O
2	 O
-	 O
6	 O
;	 O
range	 O
1	 O
-	 O
6	 O
)	 O
.	 O

A	 O
median	 O
of	 O
19	 O
cycles	 O
of	 O
[P1]	 O
BT	 O
[P2]	 O
was	 O
administered	 O
(	 O
IQR	 O
:	 O
10.5	 O
-	 O
26.5	 O
;	 O
range	 O
6	 O
-	 O
43);16	 O
patients	 O
(	 O
80	 O
%	 O
)	 O
received	 O
ten	 O
or	 O
more	 O
BT	 O
cycles	 O
.	 O

A	 O
median	 O
of	 O
19	 O
cycles	 O
of	 O
BT	 O
was	 O
administered	 O
(	 O
IQR	 O
:	 O
10.5	 O
-	 O
26.5	 O
;	 O
range	 O
6	 O
-	 O
43);16	 O
patients	 O
(	 O
80	 O
%	 O
)	 O
received	 O
ten	 O
or	 O
more	 O
[P1]	 O
BT	 O
[P2]	 O
cycles	 O
.	 O

At	 O
the	 O
time	 O
of	 O
analysis	 O
,	 O
one	 O
patient	 O
was	 O
still	 O
on	 O
treatment	 O
with	 O
[P1]	 O
BT	 O
[P2]	 O
.	 O

The	 O
[P1]	 O
BT+C	 O
arm	 O
[P2]	 O
was	 O
not	 O
expanded	 O
to	 O
second	 O
stage	 O
on	 O
account	 O
of	 O
excessive	 O
toxicity	 O
.	 O

None	 O
of	 O
the	 O
20	 O
evaluable	 O
patients	 O
in	 O
the	 O
[P1]	 O
BT+C	 O
arm	 O
[P2]	 O
died	 O
;	 O
three	 O
(	 O
15	 O
%	 O
)	 O
progressed	 O
before	 O
6	 O
months	 O
from	 O
randomisation	 O
,	 O
while	 O
17	 O
were	 O
alive	 O
and	 O
progression	 O
-	 O
free	 O
6	 O
months	 O
from	 O
study	 O
entry	 O
;	 O
therefore	 O
the	 O
PFS-6	 B-METRIC
was	 O
85	 B-RESULTS
%	 I-RESULTS
(	 I-RESULTS
95%CI	 I-RESULTS
:	 I-RESULTS
62%-97	 I-RESULTS
%	 I-RESULTS
)	 I-RESULTS
.	 O

The	 O
[P1]	 O
BT+C	 O
[P2]	 O
safety	 O
analysis	 O
population	 O
comprises	 O
20	 O
patients	 O
.	 O

In	 O
this	 O
patient	 O
[P1]	 O
carboplatin	 O
[P2]	 O
AUC	 O
4	 O
had	 O
to	 O
be	 O
reduced	 O
to	 O
AUC	 O
3	 O
and	 O
trabectedin	 O
from	 O
0.8	 O
to	 O
0.6	 O
mg	 O
/	 O
m	 O
2	 O
because	 O
of	 O
bone	 O
marrow	 O
toxicity	 O
during	 O
the	 O
first	 O
six	 O
cycles	 O
but	 O
then	 O
the	 O
bone	 O
marrow	 O
recovered	 O
,	 O
and	 O
the	 O
acute	 O
leukaemic	 O
blast	 O
crisis	 O
occurred	 O
after	 O
a	 O
further	 O
28	 O
BT	 O
cycles	 O
.	 O

In	 O
this	 O
patient	 O
carboplatin	 O
AUC	 O
4	 O
had	 O
to	 O
be	 O
reduced	 O
to	 O
AUC	 O
3	 O
and	 O
[P1]	 O
trabectedin	 O
[P2]	 O
from	 O
0.8	 O
to	 O
0.6	 O
mg	 O
/	 O
m	 O
2	 O
because	 O
of	 O
bone	 O
marrow	 O
toxicity	 O
during	 O
the	 O
first	 O
six	 O
cycles	 O
but	 O
then	 O
the	 O
bone	 O
marrow	 O
recovered	 O
,	 O
and	 O
the	 O
acute	 O
leukaemic	 O
blast	 O
crisis	 O
occurred	 O
after	 O
a	 O
further	 O
28	 O
BT	 O
cycles	 O
.	 O

In	 O
this	 O
patient	 O
carboplatin	 O
AUC	 O
4	 O
had	 O
to	 O
be	 O
reduced	 O
to	 O
AUC	 O
3	 O
and	 O
trabectedin	 O
from	 O
0.8	 O
to	 O
0.6	 O
mg	 O
/	 O
m	 O
2	 O
because	 O
of	 O
bone	 O
marrow	 O
toxicity	 O
during	 O
the	 O
first	 O
six	 O
cycles	 O
but	 O
then	 O
the	 O
bone	 O
marrow	 O
recovered	 O
,	 O
and	 O
the	 O
acute	 O
leukaemic	 O
blast	 O
crisis	 O
occurred	 O
after	 O
a	 O
further	 O
28	 O
[P1]	 O
BT	 O
[P2]	 O
cycles	 O
.	 O

The	 O
[P1]	 O
BT	 O
[P2]	 O
regimen	 O
showed	 O
worth	 O
-	 O
while	 O
clinical	 O
activity	 O
and	 O
limited	 O
toxicity	 O
that	 O
can	 O
position	 O
it	 O
as	 O
a	 O
therapeutic	 O
opportunity	 O
for	 O
women	 O
with	 O
partially	 O
platinum	 O
-	 O
sensitive	 O
disease	 O
.	 O

The	 O
apparent	 O
good	 O
activity	 O
of	 O
the	 O
[P1]	 O
BT+C	 O
[P2]	 O
regimen	 O
warrants	 O
further	 O
studies	 O
with	 O
a	 O
re	 O
-	 O
modulated	 O
schedule	 O
to	 O
limit	 O
its	 O
toxicity	 O
.	 O